Anti-SARS-CoV-2 NeutraLISA

Principle: ELISA based on competitive binding of neutralising antibodies in the sample and labelled ACE2 receptors to S1/RBD
Automation: YES
Approvals: CE-IVD
Suitability: Supports analysis of the immune response after SARS-CoV-2 infection or vaccination
Description:
Key Points:
Surrogate virus neutralisation test (sVNT) for determination of neutralising antibodies that inhibit the binding of SARS-CoV-2 S1/RBD to ACE2 receptors
Key Points:
- 100% agreement of results compared with plaque reduction neutralisation test (PRNT50)
- Established ELISA method – suitable for routine laboratory diagnostics, no BSL-3 conditions required
- Automatable even for high-throughput analysis, results available in 2 hours
Please note : Any products described on this page are
for Research Use Only and not intended for clinical diagnostic procedures unless otherwise stated.
Areas:
Tags:
Company contact details:
EUROIMMUN AG view full details
Lübeck
Germany
Website: Visit Website
Tel: +49 451 2032-0
EUROIMMUN AG view full details
Lübeck
Germany
Website: Visit Website
Tel: +49 451 2032-0